SCHEMBL4183753

SCHEMBL4183753

O=C(O)C(F)=C(F)c1ccccc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.56
CES1 P23141 3/20 0.56
ALDH1A1 P00352 4/20 0.52
ALOX15 P16050 2/20 0.52
PTPN1 P18031 1/20 0.52
ERCC5 P28715 1/20 0.52
FEN1 P39748 1/20 0.52
GAA P10253 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TDP1 Q9NUW8 1/20 0.46
NPC1 O15118 3/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 1/20 0.44
ALB P02768 1/20 0.44
RAB9A P51151 2/20 0.43
BCHE P06276 1/20 0.42
LMNA P02545 1/20 0.42
KAT6A Q92794 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL29035684 0.80 CES2 (0.52) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL5180748 0.80 CES2 (0.68) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL466255 0.77 ALDH1A1 (0.50) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL15180841 0.76 CES2 (0.77) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL6002438 0.76 CES2 (0.77) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL970209 0.75 CES2 (0.54) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL29362443 0.75 CES2 (0.68) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL30968201 0.75 CES2 (0.68) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL97828 0.75 CES2 (0.68) CES2CES1ALDH1A1ALOX15PTPN1
SCHEMBL31021561 0.75 CA12 (0.42) CES2CES1ALDH1A1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111117349-A Catalyst ink, preparation method thereof, fuel cell and vehicle 长城汽车股份有限公司 2020-05-08 CN disclosed
EP-2763221-B1 CATALYTIC INK ADJUSTMENT METHOD NISSAN MOTOR (JP) 2016-12-07 EP disclosed
CN-103782430-B The control method of catalyst ink NISSAN MOTOR CO.,LTD. (JP) 2016-05-25 CN disclosed
US-9331340-B2 Catalytic ink preparation method NISSAN MOTOR CO., LTD. (JP) 2016-05-03 US disclosed
CN-103098275-B Electrode for fuel cell and membrane electrode assembly NISSAN MOTOR 2015-04-22 CN disclosed
US-20140228200-A1 CATALYTIC INK PREPARATION METHOD NISSAN MOTOR CO., LTD. (JP) 2014-08-14 US disclosed
EP-2763221-A1 CATALYTIC INK ADJUSTMENT METHOD Nissan Motor Co., Ltd (JP) 2014-08-06 EP disclosed
CN-103782430-A Catalytic ink adjustment method NISSAN MOTOR 2014-05-07 CN disclosed
US-20130280637-A1 FUEL CELL ELECTRODE AND MEMBRANE ELECTRODE ASSEMBLY NISSAN MOTOR CO., LTD. 2013-10-24 US disclosed
EP-2626935-A1 ELECTRODE FOR FUEL CELL AND MEMBRANE ELECTRODE ASSEMBLY Nissan Motor Co., Ltd (JP) 2013-08-14 EP disclosed
CN-103098275-A Electrode for fuel cell and membrane electrode assembly NISSAN MOTOR 2013-05-08 CN disclosed
WO-2012103113-A1 PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C GILEAD PHARMASSET, LLC (US) 2012-08-02 WO disclosed
US-20090092975-A1 SELECTABLE MARKER MOLOGIC LTD (GB) 2009-04-09 US disclosed
US-7050684-B2 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL (FR) 2006-05-23 US disclosed
EP-1375527-B1 Composition comprising flourinated, radiation-curable dyes for surface energy control DRAKA COMTEQ BV (NL) 2005-12-14 EP disclosed
US-20050154078-A1 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL 2005-07-14 US disclosed
US-6844373-B2 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL (FR) 2005-01-18 US disclosed
EP-1375527-A2 Composition comprising flourinated, radiation-curable dyes for surface energy control ALCATEL (FR) 2004-01-02 EP disclosed
US-20030225178-A1 Composition comprising fluorinated, radiation-curable dyes for surface energy control ALCATEL 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090092975-A1 SELECTABLE MARKER AMD1, PADI1, PSAT1 CES2 849/4885CES1 75/4885ALDH1A1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.